Atrium to Divest Its Active Ingredients and Specialty Chemicals Division
Posted on: Tuesday, 8 April 2008, 12:00 CDT
Atrium Innovations has entered into a definitive agreement to sell its Active Ingredients and Specialty Chemicals division to AXA Private Equity for $155 million in cash, subject to working capital adjustments.
Total proceeds from the sale, including excess cash in the business, are expected to be $165 million, subject to working capital adjustments. The completion of the transaction is subject to certain customary conditions, including receipt of a limited number of regulatory approvals, but is not subject to any financing condition.
The parties expect the transaction to be completed by mid May, 2008. Following the transaction, the main office of the Active Ingredients and Specialty Chemicals division will remain in Quebec City under the leadership of Charles Boulanger, president of the Active Ingredients and Specialty Chemicals division, and its existing management team.
Pierre Fitzgibbon, president and CEO of Atrium, said: "This transaction will allow us to optimize the creation of shareholder value by focusing exclusively on the Health and Nutrition industry, where we intend to continue to play the role of a strategic consolidator in a conducive industry environment."
Source: Datamonitor
Related Articles
- Bayard Advertising Expands Into Advertising Premiums and Promotional Specialty Division
- Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care
- U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
- Walgreen to Acquire Specialty Pharmacy Business From McKesson
- Mizkan Acquires Gourmet and Specialty Foods Division of Imperial Brands
- Mediaspace Solutions Expands Media Offerings With Launch of Interactive Promotion Specialty Division
- Innospec Realigns Performance Chemicals Unit Into a Sales-Led Global Business Focused On Key Regions, Markets and Customers
- Auriga Laboratories Announces the Formation of A.T.S. Pharmaceuticals, a Specialty Division Dedicated to Dermatology and Gastroenterology
- Hormel Foods Specialty Division Increases Earnings
- Voltaix, Inc. Announces Price Increases for Electronic Specialty Gases and Chemicals
 |
 |
User Comments (0)
RSS Feeds